Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID-19 Impact on Shingles Vaccine Market
5.1. COVID-19 Landscape: Shingles Vaccine Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Shingles Vaccine Market, By Product
8.1. Shingles Vaccine Market Revenue and Volume, By Product, 2025-2033
8.1.1 Shingrix
8.1.1.1. Market Revenue and Volume Forecast (2024-2033)
8.1.2. Zostavax
8.1.2.1. Market Revenue and Volume Forecast (2024-2033)
8.1.3. SkyZoster
8.1.3.1. Market Revenue and Volume Forecast (2024-2033)
Chapter 9. Global Shingles Vaccine Market, By Vaccine Type
9.1. Shingles Vaccine Market Revenue and Volume, By Vaccine Type, 2025-2033
9.1.1. Recombinant Vaccine
9.1.1.1. Market Revenue and Volume Forecast (2024-2033)
9.1.2. Live Attenuated Vaccine
9.1.2.1. Market Revenue and Volume Forecast (2024-2033)
Chapter 10. Global Shingles Vaccine Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Volume Forecast, By Product (2024-2033)
10.1.2. Market Revenue and Volume Forecast, By Vaccine Type (2024-2033)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, By Product (2024-2033)
10.1.3.2. Market Revenue and Volume Forecast, By Vaccine Type (2024-2033)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, By Product (2024-2033)
10.1.4.2. Market Revenue and Volume Forecast, By Vaccine Type (2024-2033)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, By Product (2024-2033)
10.2.2. Market Revenue and Volume Forecast, By Vaccine Type (2024-2033)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, By Product (2024-2033)
10.2.3.2. Market Revenue and Volume Forecast, By Vaccine Type (2024-2033)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, By Product (2024-2033)
10.2.4.2. Market Revenue and Volume Forecast, By Vaccine Type (2024-2033)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, By Product (2024-2033)
10.2.5.2. Market Revenue and Volume Forecast, By Vaccine Type (2024-2033)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, By Product (2024-2033)
10.2.6.2. Market Revenue and Volume Forecast, By Vaccine Type (2024-2033)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, By Product (2024-2033)
10.3.2. Market Revenue and Volume Forecast, By Vaccine Type (2024-2033)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, By Product (2024-2033)
10.3.3.2. Market Revenue and Volume Forecast, By Vaccine Type (2024-2033)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, By Product (2024-2033)
10.3.4.2. Market Revenue and Volume Forecast, By Vaccine Type (2024-2033)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, By Product (2024-2033)
10.3.5.2. Market Revenue and Volume Forecast, By Vaccine Type (2024-2033)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, By Product (2024-2033)
10.3.6.2. Market Revenue and Volume Forecast, By Vaccine Type (2024-2033)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, By Product (2024-2033)
10.4.2. Market Revenue and Volume Forecast, By Vaccine Type (2024-2033)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, By Product (2024-2033)
10.4.3.2. Market Revenue and Volume Forecast, By Vaccine Type (2024-2033)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, By Product (2024-2033)
10.4.4.2. Market Revenue and Volume Forecast, By Vaccine Type (2024-2033)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, By Product (2024-2033)
10.4.5.2. Market Revenue and Volume Forecast, By Vaccine Type (2024-2033)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, By Product (2024-2033)
10.4.6.2. Market Revenue and Volume Forecast, By Vaccine Type (2024-2033)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, By Product (2024-2033)
10.5.2. Market Revenue and Volume Forecast, By Vaccine Type (2024-2033)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, By Product (2024-2033)
10.5.3.2. Market Revenue and Volume Forecast, By Vaccine Type (2024-2033)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, By Product (2024-2033)
10.5.4.2. Market Revenue and Volume Forecast, By Vaccine Type (2024-2033)
Chapter 11. Company Profiles
11.1. GlaxoSmithKline plc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Pfizer Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Merck & Co., Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. CanSinoBIO
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Vaccitech
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Green Cross Corp
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Genuine Life Science
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. SK Bioscience
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
著作権 ©2022 無断複写・転載を禁じます
